Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angiotech Vascular Wrap

This article was originally published in The Gray Sheet

Executive Summary

European trial begins study of 60 patients implanted with paclitaxel-eluting wrap for surgical bypass of femoral-popliteal arterial disease. The device is designed to prevent restenosis at the bypass graft anastamosis site from the outside of the vessel in a process similar to the anti-restenotic action of drug-eluting stents. Angiotech is targeting a 2005 U.S. approval of the Vascular Wrap, which will be marketed by C.R. Bard (1"The Gray Sheet, Jan 13, 2003, p. 29)...

You may also be interested in...


Vancouver-based Angiotech Pharmaceuticals will continue development of paclitaxel-eluting Vascular Wrap after Bard opts out of a 1998 $30 mil. marketing agreement. Under the deal, Angiotech was responsible for only $10 mil. in development costs; the firm now maintains it can bring the device to market without the licensing fees, milestones and royalties it was to receive from Bard. The company recently announced the launch of a 60-patient Dutch feasibility trial for treating restenosis of the femoral and popliteal arteries after bypass grafting (1"The Gray Sheet" Jan. 13, 2003, p. 29)...

Angiotech Vascular Wrap Will Bring Paclitaxel To Vascular Surgeons

Angiotech will begin clinical trials in late 2003 on its paclitaxel-eluting Vascular Wrap for prevention of restenosis following leg artery bypass surgery

Merz Consumer Care Optimistic About Future As German Lockdown Continues

Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts